Briacell Therap (NASDAQ:BCTX – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($1.50) earnings per share (EPS) for the quarter, FiscalAI reports.
Briacell Therap Stock Down 1.7%
NASDAQ BCTX traded down $0.06 on Wednesday, reaching $3.50. The company had a trading volume of 42,665 shares, compared to its average volume of 303,587. Briacell Therap has a 12 month low of $2.60 and a 12 month high of $13.43. The firm’s 50 day moving average price is $3.80 and its 200 day moving average price is $3.91. The stock has a market capitalization of $30.45 million, a PE ratio of -0.44 and a beta of 1.21.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Briacell Therap presently has an average rating of “Sell”.
Get Our Latest Research Report on Briacell Therap
Briacell Therap Company Profile
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research is centered on treatments designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on advanced breast cancer and other solid tumors.
The company’s lead technology includes Bria-IMT, an off-the-shelf, whole-cell immunotherapy derived from a breast cancer cell line. BriaCell has also been developing Bria-OTS, a personalized immunotherapy approach intended to match treatment with a patient’s human leukocyte antigen profile.
Further Reading
- Five stocks we like better than Briacell Therap
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Briacell Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therap and related companies with MarketBeat.com's FREE daily email newsletter.
